Merriman Curhan Ford Initiates Coverage on Facet Biotech (FACT) with a Buy
Tweet Send to a FriendGet Alerts FACT Hot Sheet
Price: $27.01 --0%
Rating Summary:
0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade FACT Now!
Merriman Curhan Ford initiates coverage on Facet Biotech (Nasdaq: FACT) with a Buy rating.
Merriman analyst says, "Facet Biotech represents a unique investment opportunity in the biotech space, combining a modest enterprise value, a late-stage clinical asset with a high probability of success, a robust development-stage pipeline, and an experienced management and board team with a desire and ability to succeed. The combination of modest valuation juxtaposed against latestage development increases the odds of success for investors. Facet was off the Street’s radar screen until the recent unsolicited bid from Biogen, which puts a floor of valuation under the shares in the $14-15 range."
To see more analyst ratings on FACT Click Here.
Merriman analyst says, "Facet Biotech represents a unique investment opportunity in the biotech space, combining a modest enterprise value, a late-stage clinical asset with a high probability of success, a robust development-stage pipeline, and an experienced management and board team with a desire and ability to succeed. The combination of modest valuation juxtaposed against latestage development increases the odds of success for investors. Facet was off the Street’s radar screen until the recent unsolicited bid from Biogen, which puts a floor of valuation under the shares in the $14-15 range."
To see more analyst ratings on FACT Click Here.
You May Also Be Interested In
- Topeka Capital Starts Laredo Petroleum (LPI) at Buy, Assets 'Undervalued'
- Barclays Starts Leap Wireless (LEAP) at Underweight
- WallachBeth Capital Starts Globus Medical (GMED) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
Merriman Curhan Ford
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
